Literature DB >> 2322705

Treating renal anaemia with recombinant human erythropoietin: practical guidelines and a clinical algorithm.

I C Macdougall1, R D Hutton, I Cavill, G A Coles, J D Williams.   

Abstract

Treatment with erythropoietin is highly effective and beneficial if given with care. In view of its cost, however, it is essential to exclude and treat other causes of anaemia before considering using this hormone. After treatment is started the important points for success are regular review of iron availability state combined with a slow correction of the anaemia. Failure of response requires a thorough search for a possible cause, which should be corrected before considering an increased dose of the hormone. Regular monitoring for potential complications, particularly a rise in blood pressure, is required.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2322705      PMCID: PMC1662415          DOI: 10.1136/bmj.300.6725.655

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  37 in total

1.  Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial.

Authors:  V S Lim; R L DeGowin; D Zavala; P T Kirchner; R Abels; P Perry; J Fangman
Journal:  Ann Intern Med       Date:  1989-01-15       Impact factor: 25.391

2.  Intraperitoneal erythropoietin.

Authors:  L A Frenken; P J Coppens; R G Tiggeler; R A Koene
Journal:  Lancet       Date:  1988 Dec 24-31       Impact factor: 79.321

3.  Subcutaneous erythropoietin.

Authors:  J Bommer; E Ritz; T Weinreich; G Bommer; T Ziegler
Journal:  Lancet       Date:  1988-08-13       Impact factor: 79.321

4.  Working capacity is increased following recombinant human erythropoietin treatment.

Authors:  G Mayer; J Thum; E M Cada; H K Stummvoll; H Graf
Journal:  Kidney Int       Date:  1988-10       Impact factor: 10.612

5.  Recombinant human erythropoietin therapy in haemodialysis patients--dose determination and clinical experience.

Authors:  J Bommer; C Alexiou; U Müller-Bühl; J Eifert; E Ritz
Journal:  Nephrol Dial Transplant       Date:  1987       Impact factor: 5.992

6.  Treatment of the anemia of predialysis patients with recombinant human erythropoietin: a randomized, placebo-controlled trial.

Authors:  W J Stone; S E Graber; S B Krantz; E N Dessypris; V L O'Neil; N J Olsen; T P Pincus
Journal:  Am J Med Sci       Date:  1988-09       Impact factor: 2.378

Review 7.  Recombinant human erythropoietin: implications for nephrology.

Authors:  J W Eschbach; J W Adamson
Journal:  Am J Kidney Dis       Date:  1988-03       Impact factor: 8.860

8.  Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin.

Authors:  M Moia; P M Mannucci; L Vizzotto; S Casati; M Cattaneo; C Ponticelli
Journal:  Lancet       Date:  1987-11-28       Impact factor: 79.321

Review 9.  Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy.

Authors:  A E Raine
Journal:  Lancet       Date:  1988-01-16       Impact factor: 79.321

10.  Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis.

Authors:  S Casati; P Passerini; M R Campise; G Graziani; B Cesana; M Perisic; C Ponticelli
Journal:  Br Med J (Clin Res Ed)       Date:  1987-10-24
View more
  9 in total

1.  The importance of serum transferrin receptor level in the diagnosis of functional iron deficiency due to recombinant human erythropoietin treatment in haemodialysis patients.

Authors:  H Z Tonbul; H Kaya; N Y Selçuk; S B Tekin; A San; F Akçay; E Akarsu
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

2.  Critical Realism and Empirical Bioethics: A Methodological Exposition.

Authors:  Alex McKeown
Journal:  Health Care Anal       Date:  2017-09

Review 3.  Controversies in determination of epoetin (recombinant human erythropoietin) dosages.

Authors:  P A Abraham; W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

Review 4.  Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure.

Authors:  C J Dunn; A Markham
Journal:  Drugs       Date:  1996-02       Impact factor: 9.546

5.  Comparative efficacy and safety in ESA biosimilars vs. originators in adults with chronic kidney disease: a systematic review and meta-analysis.

Authors:  Laura Amato; Antonio Addis; Rosella Saulle; Francesco Trotta; Zuzana Mitrova; Marina Davoli
Journal:  J Nephrol       Date:  2017-06-23       Impact factor: 3.902

6.  Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease.

Authors:  M E Stevens; G P Summerfield; A A Hall; C A Beck; A J Harding; J R Cove-Smith; A D Paterson
Journal:  BMJ       Date:  1992-02-22

Review 7.  Epoetin alfa. A review of its clinical efficacy in the management of anaemia associated with renal failure and chronic disease and its use in surgical patients.

Authors:  C J Dunn; A J Wagstaff
Journal:  Drugs Aging       Date:  1995-08       Impact factor: 3.923

8.  Resistance to recombinant human erythropoietin due to aluminium overload and its reversal by low dose desferrioxamine therapy.

Authors:  M Yaqoob; R Ahmad; P McClelland; K A Shivakumar; D F Sallomi; I H Fahal; N B Roberts; T Helliwell
Journal:  Postgrad Med J       Date:  1993-02       Impact factor: 2.401

Review 9.  Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.

Authors:  Suetonia C Palmer; Valeria Saglimbene; Dimitris Mavridis; Georgia Salanti; Jonathan C Craig; Marcello Tonelli; Natasha Wiebe; Giovanni F M Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2014-12-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.